Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBD-OS in Focal-Onset Seizures
NCT07233239Phase 1Recruiting
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Nov 2025
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cannabidiol in focal epilepsy, sponsored by Jazz Pharmaceuticals plc. Primary endpoint: Percent change in countable focal seizure frequency compared to baseline at 16 weeks. Started Nov 2025; status: recruiting.
02
Drugs
cannabidiol
03
Conditions
focal epilepsy
Beyond the preview
Go deeper on NCT07233239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07233239.